<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89175">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02085252</url>
  </required_header>
  <id_info>
    <org_study_id>FR-LEU-002</org_study_id>
    <secondary_id>2012-002653-35</secondary_id>
    <nct_id>NCT02085252</nct_id>
  </id_info>
  <brief_title>Phase III Study : Enantone LP 11.25 mg (Leuprorelin) Effect on the Histological Progression of Indolent Prostate Cancer</brief_title>
  <official_title>An Open-label, Multicenter, Phase III Study to Assess the Impact of Transient Androgenic Deprivation With Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase III clinical study is to assess two treatment strategies for
      indolent prostate cancer and to compare their therapeutic benefit  for management of
      patients with low-risk, localized prostate cancer (D'AMICO criteria). 2 groups of patients
      will follow after randomisation :

      Strategy A = active surveillance after a single subcutaneous injection of Enantone LP
      11.25mg or

      Strategy B = active surveillance without androgen deprivation

      The benefit should be evaluated after a twelve-month follow up based on the prostate biopsy
      results (assessed by a centralized procedure) according to the number of negative biopsies
      in each group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III randomized multi-centre, open-labelled comparative study. It is planned
      to include 240 patients in this study that will be conducted in 36 urologic centers treating
      prostate cancer.

      The trial population corresponds to patients with indolent biopsy-proved prostate cancer and
      low risk according to D'AMICO criteria.

      Patients will be selected 3 months before D0 visit starting from the results of former
      biopsies and will be definitively included in D0 according to the result of another biopsy
      that will be centrally analysed.

      Patients will be examined at six evaluation time points (M-3, D0, M3, M6, M9, M12).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comparison of the number of patients with negative biopsies at 12 months</measure>
    <time_frame>2 prostate biopsies in 12 months (at M0 / M12)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Staging biopsy comprising at least 12 cores sampled and analysed according to a centralised biopsy procedure (which confirm the results of the first biopsy [presence of positive cores localised in one third of the lobe (top, middle, bottom), the absence of core with tumour length  &gt; 3 mm and absence  grade  4  cell  ( Gleason &lt; 7)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gleason score Anxiety evaluation (HADS)/ Erectile function evaluation</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the number of patients with Gleason score  ≥ 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the progression over time of disease clinical symptoms (IPSS score)</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease clinical symptoms evaluation at each visit / 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the tumour radiological progression by dynamic MRI</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>2 MRI during the 12 months-period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the PSA levels progression</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>biological assay at each visit (every 3 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the anxiety score on HAD Scale</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>every three months at each visit by using HADs questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the International Index of Erectile Function (IIEF-5) Questionnaire</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>erectile function evaluation at each visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>• Active surveillance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>•	Active surveillance alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enantone LP 11.25 mg + Surveillance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enantone LP 11.25 mg (1 injection) + Surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enantone LP 11.25 mg (1 injection) + Surveillance</intervention_name>
    <description>Active surveillance after a single subcutaneous injection of Enantone LP 11.25mg</description>
    <arm_group_label>Enantone LP 11.25 mg + Surveillance</arm_group_label>
    <other_name>Leuproreline (Enantone) 3 months</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>active surveillance</intervention_name>
    <description>Active surveillance alone</description>
    <arm_group_label>• Active surveillance</arm_group_label>
    <other_name>Active surveillance alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical stage : T1c or T2a

          -  Staging biopsy comprising at least 12 cores sampled and analysed according to a
             centralised biopsy procedure (which confirm the results of the first biopsy [presence
             of positive cores localised in one third of the lobe (top, middle, bottom), the
             absence of core with tumour length  &gt; 3 mm and absence  grade  4  cell  ( Gleason &lt;
             7)])

          -  PSA level &lt;10 ng/ml (centralised assay)

          -  PSA density &lt; 15%

          -  Dynamic MRI criteria with confirmation of clinical stage (centralised readings)

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier CUSSENOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tenon Hospital Paris France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ouzid Mehemed, MD</last_name>
    <phone>00 33 1 46 25 16 71</phone>
    <email>mehemed.ouzid@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ouzid</name>
      <address>
        <city>Paris La Défense</city>
        <state>Paris</state>
        <zip>92977</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ouzid Mehemed, MD</last_name>
      <phone>00 33 1 46 25 16 71</phone>
      <email>mehemed.ouzid@takeda.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prof. Olivier CUSSENOT</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Cussenot, MD</last_name>
      <email>olivier.cussenot@tnn.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mehemed OUZID, MD</last_name>
      <email>mehemed.ouzid@takeda.com</email>
    </contact_backup>
    <investigator>
      <last_name>Azouzi abdel-Rahmène, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruyere Frank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chartier Eric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coloby Patrick, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Costa Pierre, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Malavaud Bernard, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rozet François, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Staerman Frédéric, Reims</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mozer Pierre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruffion Alain, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Descotes Jean-Luc, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ravery Vincent, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jung Jean-Luc, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Davin Jean-Louis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leportz Benoit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebillard Xavier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Villamizar Vesga Jorge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ansiau Jean-Pierre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rigaud Jérôme, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacqmin Didier, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irani Jacques, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Descazeaud Aurélien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amiel Jean, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benchetrit Jacques, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fendler Jean-Philippe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thuret Rodolphe, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Bernard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Houlgatte Alain, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Misrai Vincent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincendeau Sébastien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Larre Stéphane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delavierre Dominique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pfister Christian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>July 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase III, indolent prostate cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
